Introduction: Despite apparently complete surgical resection, approximately half of resected early‐stage lung cancer patients relapse and die of their disease. Adjuvant chemotherapy reduces this risk by only 5% to 8%. Thus, there is a need for better identifying who benefits from adjuvant therapy, the drivers of relapse, and novel targets in this setting. Methods: RNA sequencing and liquid chromatography/liquid chromatography–mass spectrometry proteomics data were generated from 51 surgically resected non–small cell lung tumors with known recurrence status. Results: We present a rationale and framework for the incorporation of high‐content RNA and protein measurements into integrative biomarkers and show the potential of this approach for predicting risk of recurrence in a group of lung adenocarcinomas. In addition, we characterize the relationship between mRNA and protein measurements in lung adenocarcinoma and show that it is outcome specific. Conclusions: Our results suggest that mRNA and protein data possess independent biological and clinical importance, which can be leveraged to create higher‐powered expression biomarkers.

中文翻译：

---

手术切除肺腺癌的蛋白质组学分析

简介：尽管手术切除看似完全，但大约一半切除的早期肺癌患者会复发并死于疾病。辅助化疗仅将这种风险降低 5% 至 8%。因此，需要更好地确定辅助治疗的受益者、复发的驱动因素以及在这种情况下的新目标。方法：RNA 测序和液相色谱/液相色谱-质谱蛋白质组学数据来自 51 例手术切除的已知复发状态的非小细胞肺肿瘤。结果：我们提出了将高含量 RNA 和蛋白质测量纳入综合生物标志物的基本原理和框架，并展示了这种方法在预测一组肺腺癌复发风险方面的潜力。此外，我们表征了肺腺癌中 mRNA 和蛋白质测量值之间的关系，并表明它是结果特异性的。结论：我们的结果表明 mRNA 和蛋白质数据具有独立的生物学和临床重要性，可用于创建更高功率的表达生物标志物。